Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
19356-17-3
Molecular formula
C27H44O2
Molecular weight
400.6 g/mol
Drug class
25-hydroxyvitamin D3vitamin D prohormone and precursor of calcitriol
Mechanism of action
Calcifediol (25-hydroxyvitamin D3) is converted in the kidney and other tissues to 1,25-dihydroxyvitamin D (calcitriol), which activates the vitamin D receptor and regulates calcium, phosphate and parathyroid hormone homeostasis.
Indications / reported uses
Treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency using the extended-release formulation; immediate-release products may have different vitamin D deficiency indications
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Calcifediol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Calcifediol Permitted Daily Exposure (PDE) report (the Calcifediol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Calcifediol Occupational Exposure Limit (OEL) report (the Calcifediol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.